Related Experiment Video

Updated: Aug 17, 2026

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
07:57

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Published on: January 20, 2023

Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents

Len Neckers1, Katharine Neckers

  • 1Cell and Cancer Biology Branch, National Cancer Institute, NIH, 9610 Medical Center Drive, Suite 300, Rockville, MD 20850, USA. len@helix.nih.gov

Expert Opinion on Emerging Drugs
|July 2, 2005
PubMed

Insights

Heat-shock protein 90 (Hsp90) inhibitors target cancer cell growth by degrading key signaling proteins. This approach shows promise for cancer treatment, potentially enhancing chemotherapy effectiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Heat-shock protein 90 (Hsp90) is a crucial molecular chaperone.
  • Hsp90 stabilizes mutated, overexpressed signaling proteins essential for cancer cell growth and survival.
  • Key Hsp90 client proteins include mutated p53, Bcr-Abl, Raf-1, Akt, HER2/Neu (ErbB2), and hypoxia-inducible factor-1alpha (HIF-1alpha).

Purpose of the Study:

  • To investigate the therapeutic potential of Hsp90 inhibitors in cancer treatment.
  • To explore the mechanism of action of Hsp90 inhibitors.
  • To evaluate the combination of Hsp90 inhibitors with standard chemotherapeutic agents.

Main Methods:

  • Utilizing Hsp90 inhibitors to target and destabilize Hsp90 client proteins.
  • Inducing degradation of Hsp90 client proteins.
  • Preclinical model systems were used to assess antitumour activity.
  • Phase I clinical trials are underway for specific inhibitors like 17-allylamino-geldanamycin (17-AAG).

Main Results:

  • Hsp90 inhibitors cause destabilization and degradation of Hsp90 client proteins.
  • Promising antitumour activity observed in preclinical cancer models.
  • Hsp90 inhibitors simultaneously affect multiple cancer-dependent signaling pathways.
  • 17-allylamino-geldanamycin (17-AAG) is in Phase I clinical trials.

Conclusions:

  • Hsp90 inhibitors represent a unique therapeutic strategy targeting multiple cancer pathways simultaneously.
  • Combination therapy with Hsp90 inhibitors and standard chemotherapy may significantly enhance treatment efficacy.
  • Hsp90 inhibition offers a novel approach to cancer treatment by targeting essential client proteins.

More Related Videos

Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay06:51

Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay

Published on: July 21, 2021

Intracellular Refolding Assay07:18

Intracellular Refolding Assay

Published on: January 24, 2012

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Molecular Chaperones and Protein Folding03:00

Molecular Chaperones and Protein Folding

The native conformation of a protein is formed by interactions between the side chains of its constituent amino acids. When the amino acids cannot form these interactions, the protein cannot fold by itself and needs chaperones. Notably, chaperones do not relay any additional information required for the folding of polypeptides; the native conformation of a protein is determined solely by its amino acid sequence. Chaperones catalyze protein folding without being a part of the folded protein.
The...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...